Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
share
Email Facebook Twitter Google+ LinkedIn Comments

Iridex Earnings Hold Steady in Second Quarter

BioPhotonics
Oct 2014
MOUNTAIN VIEW, Calif., Aug. 1, 2014 — Iridex Corp. earnings were relatively stable and revenue climbed 15 percent in the second quarter as the company continues to promote its laser eye treatment product.

Revenues were $10.6 million, compared to $9.2 million in the second quarter of 2013. Net income was $300,000, compared to net income in last year's second quarter of $400,000.

The company expects revenue of $10 million to $10.3 million, representing growth of 5 percent to 8 percent over last year’s third quarter.

Iridex CEO Will Moore said sales were strong for MicroPulse, a laser system for treating diabetes-related retinal disease. The results from a one-year, multicenter study of MicroPulse technology as a treatment for glaucoma were presented at the American Society of Cataract and Refractive Surgeons conference in April.

Meanwhile, Iridex’s board of directors recently established a new $3 million share repurchase program, following on another that involved buying approximately 377,000 shares at an average price of $7.97 since February 2013.

For more information, visit www.iridex.com.

AmericasBiophotonicsBusinessdiabetesglaucomaIridexlasersMicroPulseRapidScan

Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, info@photonics.com

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.